300138.SZ
晨光生物
SZSE · Consumer Defensive · C 制造业 · CN
CNY 10.96
−0.18%Year over year
Reported trailing growth
- Revenue
- -7.3%
- EBITDA
- —
- EBIT
- +119.4%
- EPS
- +121.0%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- -52.8%
- EBITDA
- -29.6%
- EPS
- -28.3%
Three-year CAGR
- Revenue
- +1.4%
- EBITDA
- -0.7%
- EBIT
- -3.6%
- Net income
- -5.3%
- EPS
- -2.1%
- Free cash flow
- -48.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026